Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women

摘要

INTRODUCTION: Female sexual interest/arousal disorder (FSIAD) is a newly defined clinical diagnosis that appears in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5). The diagnosis was previously listed as hypo-active sexual desire disorder (HSDD) in DSM-4 and as inhibited sexual desire disorder in DSM-3. References to the condition prior to 2013 (and even afterward), including research studies, often refer to the condition as HSDD.